DOI: 10.12890/2014_000036

Bilateral Panuveitis at Etanercept Initiation for Juvenile Idiopathic Arthritis

Authors

  • Kaouther Ben Abdelghani Rheumatology Department, Mongi Slim Hospital, La Marsa, Tunis University, El Manar, Tunisia
  • Marwa Slouma Rheumatology Department, Mongi Slim Hospital, La Marsa, Tunis University, El Manar, Tunisia
  • Rym Hajri Rheumatologist, private practice, Medical Office, El Manar, Tunisia
  • Leila Souabni Rheumatology Department, Mongi Slim Hospital, La Marsa, Tunis University, El Manar, Tunisia
  • Leith Zakraoui Rheumatology Department, Mongi Slim Hospital, La Marsa, Tunis University, El Manar, Tunisia

maroua.slouma@yahoo.com

Abstract

Introduction: Uveitis is a well-known extra-rheumatological manifestation of juvenile idiopathic arthritis (JIA). Tumour necrosis factor(TNF) has been used to treat uveitis associated with inflammatory diseases. A new-onset uveitis under anti-TNF therapy is uncommon.
Case presentation: A 12-year-old male, affected since the age of 6 years, by a severe form of polyarticular JIA. When etanercept was started, hepresented panuveitis bilaterally, so we switched to infliximab with good response.
Conclusions: The TNF-soluble receptor could be considered as a possible promoter in inducing endogenous new-onset uveitis in JIA.

View the entire article

Downloads

References

  1. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment, Curr Eye Res 2010;35:751–756
  2. Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003;62:88–89
  3. Martín-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis, Clin. Exp. Rheumatol. 2010;28:238–245.
  4. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF alpha agents, J. Pediatr. 2006;149:833–836.
  5. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases, Semin. Arthritis Rheum. 2011;41:503–510.
  6. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis, Rheumatology (Oxford) 2005;44:1008–1011.
  7. Scrivo R, Spadaro A, Spinelli FR, Valesini G. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al, Arthritis Rheum. 2008;58:1555–1556.
  8. Anink J, Otten MH, Gorter SL et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford) 2013;52:1674.
  9. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study, Arthritis Rheum 2007;56:3248–3252.

Published

2014-03-12

Issue

Vol. 1 No. 1 (2014)

How to Cite

1.
Ben Abdelghani K, Slouma M, Hajri R, Souabni L, Zakraoui L. Bilateral Panuveitis at Etanercept Initiation for Juvenile Idiopathic Arthritis. EJCRIM [Internet]. 2014 Mar. 12 [cited 2026 Nov. 3];1(1). Available from: https://ejcrim.com/index.php/ejcrim/article/view/36